| Recent Advances in Myasthenia Gravis |
|
Received: 25 October 2013 • Revised: 19 November 2013 • Accepted: 19 November 2013 |
| Abstract |
|
Myasthenia gravis (MG) is one of the best-known autoimmune diseases, caused by autoantibodies directed to proteins in the postsynaptic muscle membrane of the neuromuscular junction (NMJ). It is characterized by fatigue and fluctuating weakness that worsens with activity. Involvement of respiratory muscles can cause a life-threatening crisis. A better understanding of immunopathogenic mechanism has led to the development of diagnosis and therapeutic interventions. This review summarizes advances in diagnostic and therapeutic aspects of MG: the change of epidemiologic characteristics; newly-discovered antigens; old and new investigational treatments. |
| Key Words:
myasthenia gravis, acetylcholine receptor, late-onset, treatment, lipoprotein-related protein 4 |
|
PDF Links
Full text via DOI
Download Citation
